Contribution of Real‐World Evidence in European Medicines Agency's Regulatory Decision Making-Reference-Cited by-同舟云学术

Contribution of Real‐World Evidence in European Medicines Agency's Regulatory Decision Making

Author:

Bakker Elisabeth¹^ORCID,Plueschke Kelly²,Jonker Carla J.²³,Kurz Xavier²^ORCID,Starokozhko Viktoriia¹³,Mol Peter G. M.¹³⁴^ORCID

Affiliation:

1. Department of Clinical Pharmacy and Pharmacology, University Medical Centre Groningen University of Groningen Groningen The Netherlands

2. Data Analytics and Methods Task Force European Medicines Agency Amsterdam The Netherlands

3. Dutch Medicines Evaluation Board (MEB) Utrecht The Netherlands

4. Scientific Advice Working Party of the European Medicines Agency Amsterdam The Netherlands

Funder

Innovative Medicines Initiative

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

Reference56 articles.

3. European Medicines Agency.EMA regulatory science to 2025: strategic reflection (2020). Accessed April 29 2022.

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Perspective Chapter: Constant Need for Pharmacovigilance Improvement in Bosnia and Herzegovina;Pharmacovigilance - Facts, Challenges, Limitations and Opportunity [Working Title];2024-09-10